Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : North American Vaccine -- Ignore unavailable to you. Want to Upgrade?

To: Don W Stone who wrote (305)	2/24/1998 8:15:00 AM
From: Don W Stone	Read Replies (1) \| Respond to of 507

Ref: The LANCET, 1/31/98 <<<<< ANTI-VACCINE MOVEMENTS AND WHOOPING COUGH: THE CONTROVERSY CONTINUES? (pp 356-61) Controversy surrounding the use of vaccines to immunise children against pertussis (whooping cough) has been intense. Although such vaccines have been important in the control of the disease, opposition in the form of anti-vaccine movements has led to disruption in immunisation programmes. In a Review in this week's Lancet, Professor Eugene J Gangarosa and colleagues from the USA argue that, despite these movements, pertussis vaccines "continue to have an important role in global immunisation." Of vaccine-preventable diseases, pertussis rivals measles and neonatal tetanus in importance and severity among children in the developing world. Millions of cases and hundreds of thousands of deaths occur each year. Because the disease is so serious and so difficult to treat, prevention is essential. However, the investigators say that the decrease in pertussi incidence resulting from vaccination may have generated the impression that the disease was becoming milder and easier to treat; consequently, they argue, attention has shifted from the disease itself to the adverse effects that opponents believe vaccination causes such as brain damage and sudden infant death syndrome (SIDS). After extensive study of material and information on pertussis vaccines and immunisation, Gangarosa and colleagues claim that the alleged adverse effects of pertussis vaccines have been misrepresented. They go on to argue, moreover, that pertussis incidence in countries that have maintained high vaccine coverage (such as Hungary, Poland, and the USA) has been 10 to 100 times lower than in countries where immunisation was disrupted by anti-vaccine movements (such as Japan, Australia, and the UK). But they also acknowledge the beneficial effects of anti-vaccine movements, such aa encouraging the "surveillance of adverse events". Contact: Dr Eugene Gangarosa, Gangarosa International Health Foundation, 5305 Greencastle Way, Stone Mountain, Georgia, USA; tel +1 770 491 0688 Please mention The Lancet as the source of this material.>>>>>>> I posted this here because some of Dr. Ganarosa's comments from this article recently appeared in a news article but led one to believe that he was part of the anti-vaccine movement. Obviously he isn't. Now my perspective is that anything that encourages "surveillance of adverse events" is in the best interest of all . Of course such information will also further varify that the highest level of safety for the pertussis vaccine is provided by NVX's CERTIVA. TIME IS ON THE SIDE OF NVX. The SAFEST DTaP VACCINE WILL BE THE VACCINE OF CHOICE. If there is a pediatrician out there that thinks otherwise, you can bet he won't be attending to my grandchildren. Approval will come soon and at that time I will have a lot more to say. I think we all can expect to see a lot of good things happening with NVX in the next several months. :-}

To: Don W Stone who wrote (305)	2/25/1998 10:20:00 AM
From: Don W Stone	Respond to of 507

To whom ever on yahoo message board asked about analyst who now follow NVX. Right now as you know Zacks has 3 strong buys and 1 strong sell. You say their are 2 strong sells. I could care less if there are 100 strong sells. With 4 million shares short some one must be able to get their voice heard on their position. Point is the numbers don't really mean much. The short position is betting that NVX will not make it in the market place. That they won't get bought out at a price above $5 per share, that management lies, etc. What is incredible is they fail to recognize the fact that NVX will have the best pipeline of products out on the market and that NVX's marketing partner, Abbott is second to none, etc. Add to this some other facts , like small float of less than 12 million shares which is actually 95% closely held by institutions. NVX mamagement owns the rest of the o/s shares. Just about a certainty that NVX will be bought out within the year, some saying much sooner. None of this bolds well for being short NVX. Now when you think that sophisticated shorts are known to be generally very secretive about the positions they hold one can sence trouble if such is not the case. "When they go to the media with their story they are trying to create an opportunity to cover." That is a fact and it does make a lot of sense. So now you say there are 2 strong sells. This just confirms that they, the shorts are in really big trouble. I can tell you that you won't see any institutional selling on such news. The institutions that are in NVX are there for the long play. Just no way they can lose. Now go read the article in the Wall Street on Vaccine business and figure you are sitting in the best pure play out there. :-}